跳到主要內容

臺灣博碩士論文加值系統

(35.172.223.251) 您好!臺灣時間:2022/08/11 21:47
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

: 
twitterline
研究生:吳佩怡
論文名稱:硼中子捕獲治療劑─含硼胺基酸化合物之癌細胞吸收之研究
論文名稱(外文):Study on boron neutron capture thereapy (BNCT) agent-boronated amino acid uptake in tumor cells
指導教授:羅建苗
學位類別:碩士
校院名稱:國立清華大學
系所名稱:原子科學系
學門:工程學門
學類:核子工程學類
論文種類:學術論文
論文出版年:2002
畢業學年度:90
語文別:中文
中文關鍵詞:硼中子捕獲治療硼化合物Ⅵ硼胺基酸化合物Ⅷ
相關次數:
  • 被引用被引用:3
  • 點閱點閱:288
  • 評分評分:
  • 下載下載:28
  • 收藏至我的研究室書目清單書目收藏:0
碳-11標誌1-Aminocyclobutane carboxylic acid (ACBC)已由文獻報導對再復發性腦腫瘤診斷造影具有高精確度,此胺基酸在腦腫瘤正常組織的吸收比值可達10:1。本研究欲探討含硼的ACBC胺基酸衍生物1-Amino-3-(4-boronophenyl)cyclobutane carboxylic acid以做為治療腦癌或肝癌之BNCT化合物。論文主題在於此含硼胺基酸化合物之合成,並針對肝癌細胞與腦癌細胞,進行化學毒性及細胞吸收的測試。
1-Amino-3-(4-boronophenyl)cyclobutane carboxylic acid經由七個步驟之合成,起始物4-Bromostyrene可由市面商品購得,關鍵性的步驟為第一步及第二步的合成,此兩步之反應試劑在反應過程對水份子相當敏感,易造成反應不完全而導致產率過低;第六步及第七步經由Bucherer-Strecher反應後可得最終產物,惟最終產物尚含NaCl待進一步純化。以上各合成之化合物及最終產物皆經由1H-NMR及13C-NMR鑑定確認。
本實驗研究目的即利用所合成之3-(4-Boronophenyl)cyclo
butanone(compound Ⅵ)及1-Amino-3-(4-boronophenyl)cyclobutane carboxylic acid(compound Ⅷ)化合物進行腦癌細胞(G5T/VGH及GBM8901)與肝癌細胞(HepG2)吸收試驗,分別探討最大致死劑量(LD50)、毒性測試及吸收度測試,以期未來此藥物應用於動物實驗乃至臨床試驗之基礎參考依據。
由結果顯示,比較此兩種含硼化合物對癌細胞的毒性,硼化合物Ⅵ要比硼胺基酸化合物Ⅷ對癌細胞較具毒性,要達50%的致死劑量,以HepG2細胞而言,前者使用最大劑量為150 ppm,而後者的使用最大劑量可達約1000 ppm。以GBM8901細胞而言,前者藥物最大劑量為400 ppm,而後者則可達3000 ppm。以G5T/VGH細胞而言,前者最大劑量為200 ppm,而後者則最大劑量可達700 ppm。
對於細胞吸收實驗,由數據看出,肝癌細胞HepG2對硼化合物Ⅵ的吸收隨時間逐漸升高,對硼胺基酸化合物Ⅷ卻不吸收。腦癌細胞GBM8901、G5TVGH則呈現相反趨勢,對硼化合物Ⅵ不見有吸收,對硼胺基酸化合物Ⅷ則有顯著的吸收,由以上結果顯現硼化合物Ⅵ於肝癌BNCT治療的應用有極高的潛力 ; 而硼胺基酸化合物Ⅷ則對腦癌細胞BNCT治療有極高的潛力。硼化合物Ⅵ及硼胺基酸化合物Ⅷ分別對肝癌細胞及腦癌細胞之吸收量達到1013 10B /cell以上,顯現出未來應用於肝癌與腦癌BNCT治療之潛力。

11C-1-aminocyclobutane carboxylic acid (ACBC) an unnatural cyclic amino carboxylic acid, has been reported previously to be high accurate in determining recurrent brain tumors. This work has synthesized a lipophilic boron-containing cyclic amino carboxylic acid, 1-amino-3-[7-(4-borophenyl)heptyl]cyclobutane carboxylic acid, analogous to ACBC, as a BNCT drug for treatment to brain tumors and hepatoma. In the present study, cell uptake of the boron-containing amino acid in hepatoma and glioblastoma has been investigated.
1-Amino-3-(4-boronophenyl)cyclobutane carboxylic acid has been successfully synthesized via 7 steps. The key synthetic process is pertinent to the initial two steps; the reaction will become incomplete and lead to very low product-yield if the moisture exists. The last two steps involve the preparation of properly substituted cyclobutanone followed by a Bucherer-Strecker amino acid synthesis. The final product in a mixture with NaCl is tried to purify by a silica gel column chromatography. All products were identified by 1H-NMRand13C-NMR.
The products obtained from the synthesis 3-(4-boronophenyl)
cyclobutanone(compound Ⅵ) and 1-amino-3-(4-boronophenyl)cyclo
-butanecarboxylic acid(compound Ⅷ) were taken for the cell uptake test by glioblastoma (G5T/VGH and GBM8901 tumor cell)and hepatoma(HepG2 tumor cell). Experiments with respect to maximal lethal dose (LD50), chemical toxicity, radiation damage, and cell uptake extent are conducted.
Comparing the toxicity of both boron containing compounds, the 50% lethal dose of 3-(4-boronophenyl)cyclobutanone (Ⅵ) for the tumor cells of either hepatoma or glioblastoma is generaly lower than 1-amino-3-(4-boronophenyl)cyclobutane carboxylic acid(Ⅷ). For HepG2 cells, 50% lethal dose for compound Ⅵ is 150 ppm, while for compound Ⅷ is 1000 ppm. For GBM8901 cells, 50% lethal dose for compound Ⅵ is 400 ppm, while for compound Ⅷ is 4000 ppm. For G5TVGH cells, 50% lethal dose for compound Ⅵ is 200 ppm, while for compound Ⅷ is 700 ppm.
The uptake of compound Ⅵ by HepG2 cells was observed to increase with increasing the elapsed time, reaching 2.7×1014 B/cell at 48 h, while the uptake of compound Ⅷ by HepG2 cells was negligible. By contrast, the uptake of compound Ⅷ by GBM8901 cells was observed to increase initially to 4×1013 B/cell at 3 h and then decrease with increasing the elapsed time to 6.5×1011 B/cell at 48h. While the uptake of compound Ⅷ by G5T/VGH cells was observed to increase initially to 7.47×1012 B/cell at 6 h and then decrease with increasing the elapsed time to 3.59×1012 B/cell at 24h. From the results, it is revealed that compound Ⅵ may possess the potential as hepatoma BNCT drug, while compound Ⅷ may have the potential as glioblastoma BNCT drug.

摘要……………………………………………………………………….Ⅰ
英文摘要………………………………………………………………….Ⅳ
目錄……………………………………………………………………….Ⅶ
緒論………………………………………………………………………..1
材料及方法………………………………………………………………..7
一、材料………………………………………………………………..7
二、BNCT化合物合成簡介………………………………………….10
三、肝癌細胞與腦癌細胞生長曲線………………………………….17
1.方法……………………………………………………………..17
1-1 溶液的配製……………………………………………….17
1-2腫瘤細胞之培養…………………………………………..18
1-3腫瘤細胞數目之估計……………………………………..19
2.癌細胞生長曲線測定…………………………………………..20
四、癌細胞培養之化學毒性測試…………………………………….21
1. MTT分析方法…………………………………………………21
2. 毒性分析………………………………………………………26
五、BNCT化合物於細胞中吸收度測試分析……………………….28
結果與討論……………………………………………………………….31
一、BNCT化合物合成………………………………………………..31
二、肝癌細胞與腦癌細胞生長曲線測定……………………………..31
三、癌細胞培養之化學毒性測試…………………………………….32
四、BNCT化合物於細胞中吸收度測試分析………………………..33
參考文獻………………………………………………………………….35
圖表……………………………………………………………………….43
圖一、MTT, XTT, WST-1之結構及其反應產物圖………………….43
圖二、使用MTT, XTT, WST-1進行新陳代謝活性測量圖…………43
圖三、GBM8901細胞之生長曲線圖…………………………………44
圖四、G5T/VGH細胞之生長曲線圖…………………………………44
圖五、HepG2細胞之生長曲線圖…………………………………….45
圖六、硼化合物Ⅵ對GBM8901細胞之MTT測試圖………………46
圖七、硼化合物Ⅵ對G5TVGH細胞之MTT測試圖……………….46
圖八、硼化合物Ⅵ對HepG2細胞之MTT測試圖…………………….47
圖九、硼胺基酸化合物Ⅷ對GBM8901細胞之MTT測試圖…………47
圖十、硼胺基酸化合物Ⅷ對G5T/VGH細胞之MTT測試圖…………48
圖十一、硼胺基酸化合物Ⅷ對HepG2細胞之MTT測試圖………….48
圖十二、硼化合物Ⅵ對GBM8901細胞毒性測試圖…………………..49
圖十三、硼胺基酸化合物Ⅷ對GBM8901細胞毒性測試圖…………..49
圖十四、硼化合物Ⅵ對G5T/VGH細胞毒性測試圖…………………..50
圖十五、硼胺基酸化合物Ⅷ對G5T/VGH細胞毒性測試圖…………..50
圖十六、硼化合物Ⅵ對HepG2細胞毒性測試圖………………………51
圖十七、硼胺基酸化合物Ⅷ對HepG2細胞毒性測試圖………………51
表一、GBM8901細胞對硼化合物Ⅵ吸收度測定結果圖………………52
表二、GBM8901細胞對硼胺基酸化合物Ⅷ吸收度測定結果圖……...53
表三、G5T/VGH細胞對硼化合物Ⅵ吸收度測定結果圖………………54
表四、G5T/VGH細胞對硼胺基酸化合物Ⅷ吸收度測定結果圖………55
表五、HepG2細胞對硼化合物Ⅵ吸收度測定結果圖………………….56
表六、HepG2細胞對硼胺基酸化合物Ⅷ吸收度測定結果圖………….57

1.R. S. Rajiv, R. S. Robert, W. K. George. 4-Dihydroxyborylphenyl Anaiogues of 1-Aminocyclobutanecarboxylic Acids: Potential Boron Neutron Capture Therapy Agents. J. Org. Chem., 1999, 64, 8495-8500.
2.K. F. Hubner, J. A. Thie, G. T. Smith, G. W. Kabalka, I. B. Keller, A. B. Kliefoth, S. K. Campbell, E. Buonocore,. Positron Emission Tomography (PET) with 1-Aminocyclobutane-1-[11C]carboxylic Acid (1-[11C]-ACBA) for Detecting Recurrent Brain Tumors. Clinical Positron Imaging, 1998, 1, 3, 165-173.
3.H. S. Albert, T. Wemer, A. B. Beverly, R. Feng-guang, F. B. Rolf, M. C. Iwona, W. J. Gerald. The Chemistry of Neutron Capture Therapy. Chem. Rev., 1998, 98, 1515-1562.
4.K. Ono, S. I. Masunaga, M. Suzuki, Y. Kinashi, M. Takagaki, PhD, M. Akaboshi,. The Combined Effect of Boronophenylalanine And Borocaptate In Boron Neutron Capture Therapy for SCCVII Tumors in Mice. Int. J. Radiation Oncology Biol. Phys., 1999, 43, 2, 431-436.
5.G. L. Locher, Biological effects and therapeutic possibilities of neutrons. Am. J Roentgenol. Radium Ther., 1936, 36, 1-13.
6.M. Jaid, G. L. Brownell, W. H. Sweet, The possible use of neutron-capture isotopes such as boron-10 in the treatment of neoplasms. II. Computation of the radiation energy and estimates of effects in normal and neoplastic brain. J. Clin. Invest., 1952, 31, 603-610.
7.W. H. Sweet, The use of nuclear disintegrations in the diagnosis and treatment of brain tumor. N. Engl. J. Med., 1951, 245, 875-878.
8.W. H. Sweet, and M. Javid, The possible use of neutron-capturing isotopes such as boron-10 in the treatment of neoplasms. I. Intracranial tumor. J. Neurosurg., 1952, 9, 200-209.
9.M. M. Gerard, A. C. Jeffery, W. H. John, L. M. Peggy, C. Fisher. Boron neutron capture irradiation of the rat spinal cord: effects of variable doses of borocaptate sodium. Radiotherapy and Oncology, 1996, 39, 253-259.
10.O. Koji, K. Yuko, M. Shin-Ichiro, S. Minoru, T. Masao, Effect of Electroporation on Cell Killing by Boron Neutron Capture Therapy Using Borocaptate Sodium (10B-BSH). Jpn. J. Cancer Res., 1998, 89, 1352-1357.
11.S. Minoru, M. Shin-Ichro, K. Yuko, T. Masao, S. Yoshinori, K. Toru, O. Koji, The Effects of Boron Neutron Capture Therapy on Liver Tumors And Normal Hepatocytes in Mice. Jpn. J. Cancer Res., 2000, 91, 1058-1064.
12.O. Koji, M. Shin-Ichro, K. Yuko, T. Masao, A. Mitsuhiko, K. Toru, D. Eng., A. Keizo, Radiobiological Evidence Suggesting Heterogenerous of Boron Compounds in Tumors: Its Relation to Quiescent Cell Population and Tumor Cure in Neutron Capture Therapy. Int. J. Radiation Oncology Bio. Phys., 1996, 34, 5, 1081-1086.
13.M. Michiko, M. M. Gerard, L. M. Peggy, T. L. Diana, M. Y. Kelly, A. K. E. John, A. H. Duane, N. S. Daniel, M. Ruimei, A. C. Jeffrey, Boron Neutron Capture Therapy of a Murine Mammary Carcinoma Using a Lipopholic Carboranyltetraphenylporphyrin Radiation Research, 2001, 155, 603-610.
14.A. C. Jeffery, S. M. Michael, L. M. Peggy, M. N. Marta, B. L. Hungyuan, D. J. Darrel, N. S. Daniel, I. A. Howard, Derivation of Relative Biological Effectiveness for The High-LET Radiations Produced During Boron Neutron Capture Irradiations of The 9L Rat Gliosarcoma In Vitro and In Vivo. Int. J. Radiation Oncology Bio. Phys., 1993, 27, 1121-1129.
15.F. V. John, S. Paul, A new approach for the synthesis of isonitrile carborane derivatives. Ligands for metal based boron neutron capture therapy (BNCT) and boron neutron capture synovectomy (BNCS) agents. J. Inorg. Biochem,. 2001, 85, 43-51.
16.L. K. Erica, E. I. Maria, L. Juan, B. Herman, C. Osvaldo, E. S. Amanda, Boron Neutron Capture Therapy for the Treatment of Oral Cancer in the Hamster Cheek Pouch Model. Cancer Research, 2001, 61, 8638-8642.
17.L. K. Erica, E. I. Maria, D. Alejandra, G. Ricardo, F. Silvia, B. Daniel, E. S. Amanda, The Hamster Cheek Pouch as a Model of Oral Cancer for Boron Neutron Capture Therapy Studies: Selective Delivery of Boronphenylalanine. Cancer Research, 2001, 61, 8775-8781.
18.A. C. Jeffrey, D. G. John, G. F. Ralph, U. Roy, C. Scott, F. Irwin, Selective Targeting of Boronophenylalanine to Melanoma in BALB/c Mice for Neutron Capture Therapy. Cancer Research, 1987, 47, 6377-6383.
19.M. Shin-Ichiro, O. Koji, A. Mitsiyuki, Potentially Lethal Damage Repair By Quiescent Cells in Murine Solid Tumors. Int. J. Radiation Oncology Bio. Phys., 1992, 22, 973-978.
20.K. Ono, S. Masunaga, M. Akaboshi, K. Akuta, Estimation of the Initial Slope of the Cell Survival Curve after Irradiation from Micronucleus Frequency in Cytokinesis-Blocked Cells. Radiation Research, 1994, 138, S101-S104.
21.A. C. Jeffrey, D. J. Darrel, L. M. Peggy, M. N. Marta, N. S. Daniel, Control of Intracerebral Gliosarcomas in Rats by Boron Neutron Capture Therapy with p-Boronophenylalanine. Radiation Research,1992, 129, 290-296.
22.J. O. Archambeau, R. G. Fairchild, H. J. Brenneis, The response of the skin of swine to increasing absorbed doses of radiation from a thermal neutron beam, a degraded fission neutron beam, and the 10B(n , a)7Li reaction. Radiat. Res., 1971, 45, 145-165.
23.H. B. Locksley, W. H. Sweet, Tissue distribution of boron compounds in relation to neutron capture therapy of cancer. Proc. Soc. Exp. Biol. Med., 1954, 86, 56-63.
24.A. H. Soloway, Boron compounds in cancer therapy. In: H. Stainberg and A. L. McCloskey (eds.), Progress in Boron Chemistry, 1964, 1, 4, 203-234.
25.F. Alam, B. V. Bapat, A. H. Soloway, R. F. Barth, N. Mafune, D. M. Adams, Boronated compounds for neutron capture therapy. Sthralenther. Onkol., 1989, 165, 121-125.
26.J. A. Coderre, J. Kalef-Ezra, R. G. Fairchild, P. L. Micca, L. E. Reinstein, J. D. Glass, Boron neutron cancer therapy of melanoma. Cancer Res., 1988, 48, 6313-6316.
27.S. B. Kahl, P. Micca, Chemical and biological studies on boronated tetraphenyl porphyrins. In: H. Hatanaka (ed.), Neutron Capture Therapy, 1986, 61-67.
28.F. Alam, B. V. Bapat, A. H. Soloway, R. F. Barth, N. Mafune, D. M. Adams, Boronated compounds for neutron capture therapy. Sthralenther. Onkol., 1989, 165, 121-123.
29.B. H. Laster, S. B. Kahl, J. Kalef-Ezra, E. H. Popenoe, R. G. Fairchild, Biological efficacy of a boronated porphyrin as measured in cell culture. Sthralenther. Onkol., 1989, 165, 203-205.
30.D. Gabel, S. Foster, R. G. Fairchild, The Monte Carlo simulation of the biological effect of the 10B(n , a)7Li reaction in cells and tissue and its implication for boron neutron capture therapy. Radiat. Res., 1987, 111, 14-25.
31.儀器分析 上下冊 作者:林敬二、林宗義,第四版 亞美出版。
32.Cell Proliferation and Viability 2, Methods for studying cell proliferation and viability in cell populations.

QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
1. 64.劉尚志、陳佳麟,〈由Napster按評析新興科技對網路著作權之衝擊〉,《萬國法律》,第116期,2001.4
2. 62.羅明通,〈從Napster論「公開傳播權」建立之必要性─網路上資訊公開傳輸在我國著作權法定性評析〉,《智慧財產權》,2001.5
3. 60.盧映潔,〈由危險概念論網路服務提供者或網站管理人成立刑事責任之可能性〉,《國立中正大學法學集刊》,第六期,2001.
4. 59.黃惠婷,〈幫助犯之幫助行為─兼探討網路服務提供者之刑責〉,《中原財經法學》,第五期,2000
5. 58.馮震宇、胡心蘭,〈論美國著作權法合理使用原則之發展與適用〉,《中原財經法學》,第6期,2001.7
6. 57.馮震宇,〈從MP3法律爭議論網路著作權保護之未來〉,《月旦法學雜誌》,第七十四期,2001.7
7. 56.馮震宇,〈論網路科技發展對合理使用的影響與未來〉,《法令月刊》,第五十一卷第十期,2000.10
8. 70.范瑞華,〈日本法令介紹--特定電氣通信服務提供者損害賠償責任之限制暨發信者資料揭示法〉,《萬國法律》,第121期,2002.2
9. 69.蔡玉玲、許綾殷,〈從MP3.com與Napster案例談科技創新與法律〉,《法令月刊》第52卷第1期,2001.1
10. 53.尤清,〈網際網路服務提供者之法律責任─從德國及美國司法判決談起〉,《科技法律透析》,第12卷第12期,2000.12.15
11. 67.陳銘祥,〈建構網際網路的法律規範架構〉,《月旦法學雜誌》,第87期,2002.8
12. 66.陳銘祥,〈網際網路之規範上定位─從通信法規體系談起〉,《經社法制論叢》,第24期,1999.7
13. 65.陳銘祥,〈綜論網際網路的法律規範〉,《月旦法學雜誌》,第72期,2001.5
14. 49.蔡明誠,〈數位時代著作權法律問題〉,《智慧財產權》,2001.4
15. 46.陳家駿、謝銘洋,〈電腦網路上使用之著作權法律問題探討〉,《律師雜誌》,第211期,1997.4